title: Safety profile: fifteen years of clinical experience with ibuprofen.
abstract: Since its introduction in the United States in 1974, ibuprofen (Motrin, Upjohn) has been shown to be safe and effective for the treatment of pain, dysmenorrhea, inflammation, and fever. A careful review of pre-registration and postmarketing data from both patients and normal subjects clearly indicates ibuprofen's remarkable safety profile compared with that of aspirin and other commonly prescribed nonsteroidal anti-inflammatory agents. Continued safety can be anticipated on the basis of the past 15 years of review experience.
mesh_terms: D000893:Anti-Inflammatory Agents / Q000633:toxicity; D001241:Aspirin / Q000633:toxicity; D001772:Blood Cell Count; D001780:Blood Coagulation Tests; D001798:Blood Proteins / Q000378:metabolism; D002493:Central Nervous System Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000209:etiology; D004347:Drug Interactions; D004361:Drug Tolerance; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007052:Ibuprofen / Q000633:toxicity*; D007674:Kidney Diseases / Q000139:chemically induced; D008111:Liver Function Tests; D014859:Warfarin / Q000097:blood
chemical_list: D000893:Anti-Inflammatory Agents; D001798:Blood Proteins; D014859:Warfarin; D001241:Aspirin; D007052:Ibuprofen